Table 2.

Eligibility criteria

Inclusion criteria

• Histological or cytological confirmation (category V: Suspicious or VI: Malignant) of pancreatic ductal adenocarcinoma • Resectable tumor according to DPCG criteria: no arterial contact and venous contact with the superior mesenteric vein or portal vein of 90 degrees or less • No evidence for metastatic disease • WHO performance status of 0 or 1 • Ability to undergo surgery and mFOLFIRINOX chemotherapy • Leucocytes ≥ 3.0 × 109/L • Platelets ≥ 100 × 109/L • Hemoglobin ≥ 6.0 mmol/L • Renal function: eGFR ≥ 40 ml/min • Age ≥ 18 years • Written informed consent

Exclusion criteria

• Prior radiotherapy, chemotherapy, or surgery for pancreatic cancer • Prior chemotherapy precluding mFOLFIRINOX • Previous malignancy (excluding non-melanoma skin cancer, pancreatic neuroendocrine tumor (pNET) < 2 cm, and gastrointestinal stromal tumor (GIST) < 2 cm), unless no evidence of disease and diagnosed more than 3 years before diagnosis of pancreatic cancer, or with a life expectancy of more than 5 years from date of inclusion • Pregnancy or lactation • Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator